Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15897 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Patrick Schummer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30‐positive CTCL. Patients and Methods We included 14 CD30‐positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low‐dose scheme.
Results
Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow‐up of 14.4 months, median progression‐free survival was 12.0 months, with a 1‐year rate of 34.0%.
Conclusions
The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
- Skinmed AG, Lenzburg, Switzerland.
- Department of Radiotherapy and Radiooncology, University Hospital Würzburg, Würzburg, Germany.
- Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
- Medical School Hamburg, Hamburg, Germany.
ORCID-Profile: Patrick Schummer, Gabor Dobos, Matthias Goebeler, Marion Wobser
Zitieren
APA
Schummer, P., Glatzel, C., Schrüfer, P., Lawrenz, I., Dobos, G., Wehkamp, U., Hüning, S., Stranzenbach, R., Nicolay, J. P., Goebeler, M., & Wobser, M. (2025). Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15897
Vancouver
Schummer P, Glatzel C, Schrüfer P, Lawrenz I, Dobos G, Wehkamp U, et al. Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15897
BibTeX
@article{Schummer2025,
author = {Schummer, Patrick and Glatzel, Caroline and Schrüfer, Philipp and Lawrenz, Ingulf and Dobos, Gabor and Wehkamp, Ulrike and Hüning, Svea and Stranzenbach, René and Nicolay, Jan P and Goebeler, Matthias and Wobser, Marion},
title = {Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15897}
}
EUVIMED